|
12 Nov 2019 |
Social |
RT @EBRheum: #ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA
Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u availa… |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: Ixekizumab in nrAXSpa
Outcomes met. Another positive trial
#ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: Ixekizumab in nrAXSpa: COAST-X
switch at wk16 for 52wk study
IXE 2wkly vs 4wkly vs PBO
303pts
#ACR19 @rheumnow Abst2729 |
|
|
12 Nov 2019 |
Social |
Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH |
|
|
12 Nov 2019 |
Social |
RT @EBRheum: #ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa
Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.… |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: Upadacitinib in AS
Nice to the rapid response
#ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: Upadacitinib in AS
And here’s the Safety Slide
#ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: EAMs: I know there's published data but among Axial SpA patients you actually see, what is the most common EAM?
@rheum… |
|
|
12 Nov 2019 |
Social |
RT @philipcrobinson: Use of complementary and alternative medicines in #psoriatic arthritis Abs 2462 #ACR19 @RheumNow https://t.co/h8UTbOwW… |
|
|
12 Nov 2019 |
ACR Video |
Domain Strategy and Treatment in Psoriatic Arthritis: Dr. Elaine Husni |
|
|
12 Nov 2019 |
ACR Video |
Depression in Psoriatic Arthritis: Dr. Olga Petryna |
|
|
12 Nov 2019 |
Social |
RT @DrPetryna: #ACR19 @rheumnow ABS2439 retrospective cohort study of PSA +HUC/gout shows HUC independently associated w/CVD, mainly w/ Afi… |
|
|
12 Nov 2019 |
Social |
RT @philipcrobinson: My write-up of data on IL-17 Inhibitors In Non-Radiographic Axial SpA presented here at #ACR19 @rheumnow https://t.co/… |
|
|
12 Nov 2019 |
Social |
RT @_connectedcare: Bullish on value of Polygenic Risk scores to help diagnose Axial SpA (not commercially available yet)
#ACR19 @rheumnow… |
|
|
11 Nov 2019 |
Social |
RT @_connectedcare: Do you agree there is so much IBD in our SpA patients?
#ACR19 @rheumnow 4M064 https://t.co/0IDujdyZdu |
|
|
11 Nov 2019 |
Social |
RT @EBRheum: RCT Tildrakizumab (IL23i) in Psoriatic Arthritis
Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% imp… |
|
|
11 Nov 2019 |
Social |
RT @synovialjoints: Continued Ixekizumab was superior to PBO in maintaining MDA in biologic-naïve PsA pts who achieved sustained MDA on ini… |
|
|
11 Nov 2019 |
Social |
RT @MaeveGamble: If 50% of SpA pts have microscopic bowel disease, 10% have clinically significant bowel disease...should all patients diag… |
|
|
11 Nov 2019 |
Social |
RT @philipcrobinson: Exciting phase 2 data on bimekizumab (dual anti-17A and F) in r-axSpA, looks like 160mg is the go, I hear on the grape… |
|
|
11 Nov 2019 |
Social |
RT @DrPetryna: #ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 C… |
|
